Summit Therapeutics Inc (SMMT)

8.685 -2.24 (-20.47%) USD  |  NASDAQ  |  May 31, 16:00
8.70 +0.02 (+0.17%) After-Hours: 20:00
More

Summit Therapeutics Research and Development Expense (Quarterly): 30.87M for March 31, 2024

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2013. Upgrade now.
Date Value
March 31, 2024 30.87M
December 31, 2023 24.81M
September 30, 2023 15.32M
June 30, 2023 9.451M
March 31, 2023 9.883M
December 31, 2022 5.386M
September 30, 2022 17.05M
June 30, 2022 9.008M
March 31, 2022 20.56M
December 31, 2021 23.11M
September 30, 2021 19.94M
June 30, 2021 23.92M
March 31, 2021 18.38M
December 31, 2020 19.96M
September 30, 2020 11.17M
June 30, 2020 11.00M
March 31, 2020 11.15M
October 31, 2019 9.319M
July 31, 2019 10.60M
April 30, 2019 10.70M
January 31, 2019 11.40M
Date Value
October 31, 2018 10.41M
July 31, 2018 13.03M
April 30, 2018 15.96M
January 31, 2018 15.79M
October 31, 2017 9.810M
July 31, 2017 8.685M
April 30, 2017 6.510M
January 31, 2017 6.394M
October 31, 2016 4.830M
July 31, 2016 7.134M
April 30, 2016 7.023M
January 31, 2016 5.709M
October 31, 2015 6.946M
July 31, 2015 6.590M
April 30, 2015 4.832M
January 31, 2015 3.471M
October 31, 2014 4.152M
July 31, 2014 4.201M
April 30, 2014 4.309M
January 31, 2014 3.909M
October 31, 2013 3.820M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

5.386M
Minimum
Dec 2022
30.87M
Maximum
Mar 2024
15.84M
Average
15.32M
Median
Sep 2023

Research and Development Expense (Quarterly) Benchmarks

Merck & Co Inc 3.992B
Novo Integrated Sciences Inc --
Insmed Inc 121.08M
Retractable Technologies Inc 0.1423M
BioCardia Inc 1.241M